This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Vertex Pharmaceuticals (Nasdaq: VRTX) and Ono Pharmaceutical (OTCMKTS: OPHLY) have announced an exclusive collaboration, for the development and commercialization of Vertex's povetacicept in Japan ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy appears to be paying off so far.

OSAKA, Japan & BOSTON, June 23, 2025--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Vertex Pharmaceuticals ...

OSAKA, Japan & BOSTON, June 23, 2025--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Vertex Pharmaceuticals Incorporated (Headquarters: Boston, ...

BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license ...

Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: [email protected] or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 Ono ...